Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCirata Regulatory News (CRTA)

Share Price Information for Cirata (CRTA)

Share Price is delayed by 15 minutes
Get Live Data
16.05    -0.95 (-5.59%)
Bid:
16.05
Ask:
16.95
Spread: 0.90 (5.607%)
Market Cap: £20.30m
CRTA Live PriceLast checked at - London Stock Exchange

Intraday Cirata Share Chart

Q1 FY24 Trading Update

9 Apr 2024 07:00

RNS Number : 7644J
Cirata PLC
09 April 2024
 

9 April 2024

 

Cirata plc

("Cirata" or the "Company")

Q1 FY24 Trading Update

 

GTM and sales organization embedded for growth

 

 

Cirata plc (LSE: CRTA), announces a trading update for the quarter period ended March 31, 2024.  An accompanying video presentation and discussion can be found on the Cirata Investor Relations webpage here.

 

Summary

· Bookings for the period of $0.7m

· Steady build in pipeline

· Sales and partner activity increased

· Fifteen contracts signed, improved mix to "new and growth"

· Important new business secured in re-invigorated DevOps offering

· New releases of Live Data Migrator (LDM) and major release of DevOps (ALM)

· Cash position at the end March was $13.3m

· Management reconfirms FY24 bookings guidance of $13-15m (81%-108% YoY growth)

 

Trading update

 

Bookings in Q1 FY24 were $0.7m (Q1 FY23: $2.1m, which benefitted from a large renewal), with DevOps/Application Lifecycle management ("DevOps") software accounting for 51% of bookings and Data Integration ("DI") software accounting for 49% of bookings.

 

In total, fifteen contracts were signed in the quarter, nine of which were new and growth[1] contracts. This included two new contracts in DevOps, secured with Onsemi and Marvell Technology. The new subscription contract with Onsemi in DevOps represents the first positive step in the reboot of the DevOps business. New DI contracts included deals signed with the Bank of Nova Scotia, Westpac Banking Corp and a large African financial services group. We also saw further growth at Tesco, a returning customer. Two deals secured in Q1 were greater than $150K in value: one in DI and the other in DevOps. 

 

Technology is core to Cirata and its market differentiation. Further progress was made in Q1 on shaping the product roadmap with direct customer input for LDM. In DevOps, we announced the availability of Gerrit 3.7, and we are already in discussions with customers on Proof of Concept.

 

As previously outlined, deal slippage remained a feature of Q1 performance. Some of the orders that were targeted for FY23 Q4 closed in early FY24 and, similarly, some of the deals targeted for Q1 have also slipped with the expectation that these will now conclude in Q2. Issues contributing to slippage include the complex nature of enterprise sales for data integration, protracted procurement processes and the ramping of the new sales team. Establishing greater sales cycle predictability, therefore, remains a key priority for management, to move beyond the current non-linear growth trajectory. To that end, Q1 saw the final changes made to the company's Sales organization. With that complete, Management believes that the foundations are now, for the first time, in place to deliver steadily improving pipeline predictability and performance.

 

As previously reported, Management expects that bookings will be H2 weighted in FY24 as the pipeline builds and the Sales team becomes more proven. The FY24 bookings guidance, which Management reconfirms today, is based on an expectation of higher levels of sales activity, both direct and through partners, and on the current sales pipeline. The new GTM organization is bedding down and leads from partners and customer activity levels are increasing and contributing to pipeline growth.

 

A table of key performance indicators will be posted to the Investor Relations landing page Cirata KPI by 30 April 2024.

 

 

Stephen Kelly, Chief Executive Officer, commented.

 

"I want to provide a balanced scorecard and honest perspective on the progress of Cirata. We were disappointed by the actual Q1 bookings and again experienced deal slippage relating to the complex nature of enterprise sales, protracted procurement processes and the ongoing ramping of our new sales team. However, I am pleased with the increasing level of sales activity in the quarter, following the complete reboot of the GTM organization.

 

The cadence of customer interaction has ramped significantly, and we are seeing improved commercial re-engagement as evidenced by the range of logos we have contracted with in Q1. Signing our first new contract in DevOps for some years as well as securing new and returning logos in DI has been encouraging and energizing for our team. Innovation in both LDM and DevOps continues and provides differentiated and superior technology offerings for our customers.

 

As I said before, the recovery of Cirata, is likely to be non-linear but no-one should underestimate the focus we are placing on sharpening and improving our pipeline visibility and predictability. With the sales team now fully set, and with partner and customer interactions building, we remain focused on delivering against the guidance range and phasing we have set out for the year as a whole."

 

 

This announcement contains information that qualifies or may qualify as inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

The person responsible for arranging the release of this announcement on behalf of Cirata plc is Larry Webster, Company Secretary. 

 

 

For further information, please contact: 

 

Cirata

Via FTI Consulting

Stephen Kelly, Chief Executive Officer

Ijoma Maluza, Chief Financial Officer

Daniel Hayes, Investor Relations

FTI Consulting

+44 (0)20 3727 1137

Matt Dixon /Kwaku Aning / Usama Ali

Stijfel (Nomad and Joint Broker)

+44 (0)20 7710 7600

Fred Walsh / Richard Short / Tom Marsh

Liberum (Joint Broker)

+44 (0)20 3100 2000

Max Jones / Edward Mansfield / John More

 

About Cirata

 

Cirata, accelerates data-driven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption. With Cirata, data leaders can leverage the power of AI and analytics across their entire enterprise data estate to freely choose analytics technologies, avoid vendor, platform, or cloud lock-in while making AI and analytics faster, cheaper, and more flexible. Cirata's portfolio of products and technology solutions make strategic adoption of modern data analytics efficient and automated. For more information about Cirata, visit www.cirata.com

 


[1] New & Growth refers to either a new contract or additional consumption on an existing contract.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSIEFAELSELL
Date   Source Headline
1st Jun 20267:00 amRNSBlock Listing Return
20th May 20267:00 amRNSResult of AGM
5th May 20267:00 amRNSHolding(s) in Company
23rd Apr 20268:52 amRNSAmendment to Notice of Annual General Meeting
21st Apr 20267:00 amRNSGrant of Awards & PDMR Dealing
14th Apr 20267:00 amRNSTrading Statement
31st Mar 20263:39 pmRNSManagement Changes
31st Mar 20267:00 amRNSPreliminary Results
4th Feb 20268:54 amRNSGrant of Awards & PDMR Dealing
14th Jan 20267:00 amRNSQ4 FY25 Trading Update
19th Dec 20252:50 pmRNSDevOps Final Consideration Received
19th Dec 20252:50 pmRNSDevOps Final Consideration Received
1st Dec 20259:35 amRNSBlock Listing Return
27th Nov 20257:00 amRNSFinancial Conduct Authority Update
17th Nov 20257:00 amRNS$6.7m Multiyear Contract win
27th Oct 202510:05 amRNSNotification of Major Holdings
16th Oct 20257:00 amRNSTrading Statement
13th Oct 20257:00 amRNS$3.1m Multiyear Contract with leading US Insurer
12th Sep 202511:02 amRNSGrant of Awards & PDMR Dealing
10th Sep 20257:00 amRNSNotification of Major Holdings
9th Sep 20258:00 amRNS-RCirata launches new data platform
3rd Sep 20257:00 amRNSInterim results
13th Aug 20257:00 amRNSGrant of Share Options to PDMRs
11th Aug 20257:00 amRNSCompletion of DevOps Divestment
15th Jul 20257:07 amRNSQ2 and H1FY25 Trading Update
30th Jun 20257:01 amRNSHolding(s) in Company
30th Jun 20257:00 amRNS$700K Multiyear Data Integration Contract Renewal
10th Jun 20257:00 amRNSBoard Appointment
3rd Jun 20252:39 pmRNSBlock Listing Return
8th May 20254:47 pmRNSResult of AGM
29th Apr 202511:44 amRNSGrant of Share Options to PDMRs
16th Apr 20257:00 amRNSQ1FY25 Trading Statement
8th Apr 20257:00 amRNSAnnual Report & Notice of AGM
2nd Apr 20253:51 pmRNSNotification of Major Holdings
31st Mar 20257:01 amRNSContract win
31st Mar 20257:00 amRNSPreliminary Results
27th Feb 20257:00 amRNSNew logo in Telecom sector
20th Feb 20257:00 amRNSTotal Voting Rights
20th Jan 20256:29 pmRNSPDMR dealings and Total Voting Rights
9th Jan 20257:00 amRNSQ4FY24 Trading Update
16th Dec 20247:00 amRNSContract Win and FY24 Guidance
13th Dec 20243:46 pmRNSVesting of Restricted Stock & Director Dealings
11th Dec 20247:00 amRNSIssue of Equity
9th Dec 20247:00 amRNSMarvell Contract Renewal
2nd Dec 20243:40 pmRNSBlock Listing Return
1st Nov 20247:00 amRNSGrant of Share Options to PDMRs
24th Oct 20247:00 amRNSPDMR Transactions
9th Oct 20247:00 amRNSQ3 Trading Update and Outlook
2nd Oct 20243:19 pmRNSAmendment of OEM sales partnership with IBM
1st Oct 20247:00 amRNSBoard Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.